Propagation and quantification of obligate intracellular pathogens are both labor-intensive and costly undertakings. These characteristics, coupled with C. burnetii's highly infectious nature and select agent designation, complicate the most basic research endeavors. However, because highly purified and enumerated C. burnetii is essential to the proposed research, a dedicated core facility with BSL 3 containment, highly trained technical personnel, and an archival system is proposed. Thus, the purpose of the Core B is to make available to each of the 4 Montana Coxiella projects expertise in the cultivation, purification, enumeration, and archiving of phase 1 and 2 Coxiella burnetii. The core will be located at Montana State University, the location of the BSL-3 facilities, and will be directed by Allen Harmsen of Montana State University. Collaborations among projects. Core B will provide services to each of the 4 research projects of the Montana Coxiella group as well as any other RMRCE investigator needing their service. These services will include making standardized inocula of phase 1 and 2 Coxiella burnetii as well as the Crazy strain of Coxiella, as well as the services of standardized Coxiella enumeration and archival of Coxiella organisms. In addition, the two part- time technicians are trained specifically in doing lung infections in mice in the BSL-3. When not engaged in their other activities, the Core B technicians will be available to assist the 4 Montana Coxiella projects on days they sacrifice mice since these time points are labor intensive. Our BSL3 SOP requires a "buddy system" and individuals are not allowed to work alone in the facility. It is much more economical to have two part time floating positions rather than for each of the individual research projects to fund full time technicians to cover these occasional, labor-intensive time points. Therefore, the core is integral and critical to the goals of each of the projects and required for consistency between projects so that results between projects can be directly compared. Core B will support the RMRCE Integrated Research Foci on Immunomodulation, Adjuvants and Vaccines (IRF 1) as well as Bacterial Therapeutics (IRF 2), and its resources will be utilized by RPs 1.1, 1.2, 1.3, and 2.4.

Public Health Relevance

The RMRCE Coxiella projects are designed to collectively develop non-specific adjuvants and specific vaccines to Q fever. The Core will supply a consistent and well characterized source of C. burnetii so that results of experiments by any one of the projects can be compared to results from the other projects. Thus, the core is central to the development of immunotherapies against Q fever.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-DDS-M)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Colorado State University-Fort Collins
Fort Collins
United States
Zip Code
Gibson, Christopher C; Zhu, Weiquan; Davis, Chadwick T et al. (2015) Strategy for identifying repurposed drugs for the treatment of cerebral cavernous malformation. Circulation 131:289-99
Wang, Hong; Siddharthan, Venkatraman; Hall, Jeffery O et al. (2014) Autonomic deficit not the cause of death in West Nile virus neurological disease. Clin Auton Res 24:15-23
Scharton, Dionna; Bailey, Kevin W; Vest, Zachary et al. (2014) Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment. Antiviral Res 104:84-92
Shives, Katherine D; Beatman, Erica L; Chamanian, Mastooreh et al. (2014) West nile virus-induced activation of mammalian target of rapamycin complex 1 supports viral growth and viral protein expression. J Virol 88:9458-71
Calvert, Amanda E; Dixon, Kandice L; Delorey, Mark J et al. (2014) Development of a small animal peripheral challenge model of Japanese encephalitis virus using interferon deficient AG129 mice and the SA14-14-2 vaccine virus strain. Vaccine 32:258-64
Richert, Laura E; Rynda-Apple, Agnieszka; Harmsen, Ann L et al. (2014) CD11cýýý cells primed with unrelated antigens facilitate an accelerated immune response to influenza virus in mice. Eur J Immunol 44:397-408
Soffler, Carl; Bosco-Lauth, Angela M; Aboellail, Tawfik A et al. (2014) Pathogenesis of percutaneous infection of goats with Burkholderia pseudomallei: clinical, pathologic, and immunological responses in chronic melioidosis. Int J Exp Pathol 95:101-19
Porta, Jason; Jose, Joyce; Roehrig, John T et al. (2014) Locking and blocking the viral landscape of an alphavirus with neutralizing antibodies. J Virol 88:9616-23
Jones-Carson, Jessica; Zweifel, Adrienne E; Tapscott, Timothy et al. (2014) Nitric oxide from IFN?-primed macrophages modulates the antimicrobial activity of ?-lactams against the intracellular pathogens Burkholderia pseudomallei and Nontyphoidal Salmonella. PLoS Negl Trop Dis 8:e3079
Phillips, Aaron T; Schountz, Tony; Toth, Ann M et al. (2014) Liposome-antigen-nucleic acid complexes protect mice from lethal challenge with western and eastern equine encephalitis viruses. J Virol 88:1771-80

Showing the most recent 10 out of 181 publications